India · Delayed Price · Currency is INR Torrent Pharmaceuticals Statistics
Total Valuation
NSE:TORNTPHARM has a market cap or net worth of INR 1.90 trillion. The enterprise value is 2.11 trillion.
| Market Cap | 1.90T |
| Enterprise Value | 2.11T |
Important Dates
The next estimated earnings date is Tuesday, October 27, 2026.
| Earnings Date | Oct 27, 2026 |
| Ex-Dividend Date | May 29, 2026 |
Share Statistics
| Current Share Class | 380.37M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +3.10% |
| Shares Change (QoQ) | +12.62% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 18.58% |
| Float | 146.84M |
Valuation Ratios
The trailing PE ratio is 86.92 and the forward PE ratio is 68.77.
| PE Ratio | 86.92 |
| Forward PE | 68.77 |
| PS Ratio | 12.06 |
| PB Ratio | 10.78 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 80.85 |
| P/OCF Ratio | 62.73 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 43.51, with an EV/FCF ratio of 90.17.
| EV / Earnings | 96.95 |
| EV / Sales | 13.45 |
| EV / EBITDA | 43.51 |
| EV / EBIT | 57.47 |
| EV / FCF | 90.17 |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.85 |
| Debt / EBITDA | 3.09 |
| Debt / FCF | 6.41 |
| Interest Coverage | 5.81 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 9.15% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | 4.87% |
| Revenue Per Employee | 8.61M |
| Profits Per Employee | 1.19M |
| Employee Count | 18,258 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NSE:TORNTPHARM has paid 7.11 billion in taxes.
| Income Tax | 7.11B |
| Effective Tax Rate | 24.80% |
Stock Price Statistics
The stock price has increased by +37.53% in the last 52 weeks. The beta is 0.14, so NSE:TORNTPHARM's price volatility has been lower than the market average.
| Beta (5Y) | 0.14 |
| 52-Week Price Change | +37.53% |
| 50-Day Moving Average | 4,946.08 |
| 200-Day Moving Average | 4,415.09 |
| Relative Strength Index (RSI) | 54.09 |
| Average Volume (20 Days) | 329,650 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:TORNTPHARM had revenue of INR 157.23 billion and earned 21.81 billion in profits. Earnings per share was 62.51.
| Revenue | 157.23B |
| Gross Profit | 119.46B |
| Operating Income | 36.80B |
| Pretax Income | 28.67B |
| Net Income | 21.81B |
| EBITDA | 48.14B |
| EBIT | 36.80B |
| Earnings Per Share (EPS) | 62.51 |
Balance Sheet
The company has 23.55 billion in cash and 150.26 billion in debt, with a net cash position of -126.70 billion.
| Cash & Cash Equivalents | 23.55B |
| Total Debt | 150.26B |
| Net Cash | -126.70B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 175.85B |
| Book Value Per Share | 247.85 |
| Working Capital | n/a |
Cash Flow
In the last 12 months, operating cash flow was 30.23 billion and capital expenditures -6.77 billion, giving a free cash flow of 23.45 billion.
| Operating Cash Flow | 30.23B |
| Capital Expenditures | -6.77B |
| Depreciation & Amortization | 11.34B |
| Net Borrowing | 118.67B |
| Free Cash Flow | 23.45B |
| FCF Per Share | n/a |
Margins
Gross margin is 75.98%, with operating and profit margins of 23.40% and 13.87%.
| Gross Margin | 75.98% |
| Operating Margin | 23.40% |
| Pretax Margin | 18.24% |
| Profit Margin | 13.87% |
| EBITDA Margin | 30.62% |
| EBIT Margin | 23.40% |
| FCF Margin | 16.78% |
Dividends & Yields
This stock pays an annual dividend of 38.00, which amounts to a dividend yield of 0.76%.
| Dividend Per Share | 38.00 |
| Dividend Yield | 0.76% |
| Dividend Growth (YoY) | 18.75% |
| Years of Dividend Growth | 2 |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3.10% |
| Shareholder Yield | -2.33% |
| Earnings Yield | 1.15% |
| FCF Yield | 1.24% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for NSE:TORNTPHARM is 5,430.93, which is 9.25% higher than the current price. The consensus rating is "Buy".
| Price Target | 5,430.93 |
| Price Target Difference | 9.25% |
| Analyst Consensus | Buy |
| Analyst Count | 28 |
| Revenue Growth Forecast (3Y) | 21.32% |
| EPS Growth Forecast (3Y) | 21.22% |
Stock Splits
The last stock split was on July 8, 2022. It was a forward split with a ratio of 2.
| Last Split Date | Jul 8, 2022 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |